All severe (or clinically severe) hemophiliacs receive prophylactic home therapy in Iceland. Others receive on demand treatment. Only recombinant factors have been used for hemophilia A and B since 1998.
The products in use are Recombinate from Baxter, Helixate NexGen from Aventis and Benefix from Baxter.
Every hemophiliac and patients with other bleeding disorders, such as von Willebrand disease and Bernard-Soulier syndrome are invited for regular visits at the hemophilia centre or the Children´s Hospital. The frequency depends upon age, severity and other health related issues.